Nuvilex (PMCB) Competitors $1.14 +0.03 (+2.25%) As of 09:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMCB vs. SXTC, FBLG, EYEN, TPST, COEP, KALA, ALXO, GBIO, TENX, and CARAShould you be buying Nuvilex stock or one of its competitors? The main competitors of Nuvilex include China SXT Pharmaceuticals (SXTC), FibroBiologics (FBLG), Eyenovia (EYEN), Tempest Therapeutics (TPST), Coeptis Therapeutics (COEP), KALA BIO (KALA), ALX Oncology (ALXO), Generation Bio (GBIO), Tenax Therapeutics (TENX), and Cara Therapeutics (CARA). These companies are all part of the "pharmaceutical products" industry. Nuvilex vs. Its Competitors China SXT Pharmaceuticals FibroBiologics Eyenovia Tempest Therapeutics Coeptis Therapeutics KALA BIO ALX Oncology Generation Bio Tenax Therapeutics Cara Therapeutics Nuvilex (NASDAQ:PMCB) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings. Which has better earnings & valuation, PMCB or SXTC? Nuvilex has higher earnings, but lower revenue than China SXT Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvilexN/AN/A$330K$0.741.53China SXT Pharmaceuticals$1.93M107.31-$3.10MN/AN/A Which has more risk and volatility, PMCB or SXTC? Nuvilex has a beta of -0.42, indicating that its stock price is 142% less volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Do insiders and institutionals have more ownership in PMCB or SXTC? 34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 10.2% of Nuvilex shares are owned by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to PMCB or SXTC? In the previous week, China SXT Pharmaceuticals had 1 more articles in the media than Nuvilex. MarketBeat recorded 1 mentions for China SXT Pharmaceuticals and 0 mentions for Nuvilex. Nuvilex's average media sentiment score of 0.00 equaled China SXT Pharmaceuticals'average media sentiment score. Company Overall Sentiment Nuvilex Neutral China SXT Pharmaceuticals Neutral Is PMCB or SXTC more profitable? Nuvilex's return on equity of 0.51% beat China SXT Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NuvilexN/A 0.51% 0.35% China SXT Pharmaceuticals N/A N/A N/A SummaryNuvilex beats China SXT Pharmaceuticals on 5 of the 8 factors compared between the two stocks. Get Nuvilex News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMCB vs. The Competition Export to ExcelMetricNuvilexMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.79M$2.43B$5.53B$9.02BDividend YieldN/A1.78%5.22%3.99%P/E Ratio1.539.1527.8120.25Price / SalesN/A680.43429.10119.26Price / CashN/A21.7726.2128.59Price / Book0.354.558.025.65Net Income$330K$31.26M$3.18B$249.15M7 Day Performance4.13%2.98%2.88%2.91%1 Month Performance11.27%3.46%1.66%4.11%1 Year Performance-45.69%0.77%34.25%20.98% Nuvilex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMCBNuvilex0.8922 of 5 stars$1.14+2.3%N/A-47.3%$7.79MN/A1.534Gap UpSXTCChina SXT Pharmaceuticals0.143 of 5 stars$1.75-4.9%N/A-78.1%$27.70M$1.93M0.0090FBLGFibroBiologics2.5375 of 5 stars$0.72-0.1%$13.00+1,705.6%-87.0%$27.55MN/A-3.4310Gap UpEYENEyenovia1.0003 of 5 stars$9.56+74.5%$2.00-79.1%-77.1%$27.53M$60K-0.1640Analyst UpgradeHigh Trading VolumeTPSTTempest Therapeutics1.619 of 5 stars$7.08+3.4%$30.00+323.7%-72.8%$26.05MN/A-0.3920COEPCoeptis Therapeutics0.1963 of 5 stars$7.39+4.8%N/A+35.6%$25.94MN/A-1.272Gap UpKALAKALA BIO3.3789 of 5 stars$3.99-0.7%$13.50+238.3%-23.3%$25.74M$3.89M-0.4830ALXOALX Oncology2.6406 of 5 stars$0.47+2.4%$3.30+601.1%-91.4%$25.13MN/A-0.1940Negative NewsGBIOGeneration Bio2.9536 of 5 stars$0.37+3.0%$7.33+1,877.7%-83.9%$24.86M$24.56M-0.34150TENXTenax Therapeutics1.2656 of 5 stars$5.90+4.9%$17.50+196.9%+88.0%$24.46MN/A-2.389CARACara Therapeutics0.3386 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading Volume Related Companies and Tools Related Companies SXTC Competitors FBLG Competitors EYEN Competitors TPST Competitors COEP Competitors KALA Competitors ALXO Competitors GBIO Competitors TENX Competitors CARA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMCB) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvilex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
